These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 35718266)
1. In vitro susceptibilities of isolates of potentially naturally inducible chromosomal AmpC-producing metallo-β-lactamase-negative carbapenem-resistant Enterobacterales species to ceftazidime-avibactam: Data from the Antimicrobial Testing Leadership and Surveillance Programme, 2012-2019. Jean SS; Lee YL; Hsu CW; Hsueh PR Int J Antimicrob Agents; 2022 Sep; 60(3):106617. PubMed ID: 35718266 [TBL] [Abstract][Full Text] [Related]
2. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals. Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421 [TBL] [Abstract][Full Text] [Related]
3. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values. Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206 [TBL] [Abstract][Full Text] [Related]
4. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018). Piérard D; Stone GG BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341 [TBL] [Abstract][Full Text] [Related]
5. Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020. Lee YL; Ko WC; Hsueh PR Int J Antimicrob Agents; 2022; 60(5-6):106679. PubMed ID: 36241011 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity of Ceftazidime-Avibactam and its comparators against Carbapenem resistant Enterobacterales collected across India: results from ATLAS surveillance 2018 to 2019. Bakthavatchalam YD; Routray A; Mane A; Kamat S; Gupta A; Bari AK; Rohit A; Poojary A; Mukherjee DN; Sethuraman N; Munshi N; Shah S; Balaji V; Gupta Y Diagn Microbiol Infect Dis; 2022 May; 103(1):115652. PubMed ID: 35255290 [TBL] [Abstract][Full Text] [Related]
8. Assessment of Ceftazidime-Avibactam 30/20-μg Disk, Etest versus Broth Microdilution Results When Tested against Han R; Yang X; Yang Y; Guo Y; Yin D; Ding L; Wu S; Zhu D; Hu F Microbiol Spectr; 2022 Feb; 10(1):e0109221. PubMed ID: 35019685 [TBL] [Abstract][Full Text] [Related]
9. Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance. Mushtaq S; Vickers A; Woodford N; Livermore DM Int J Antimicrob Agents; 2024 Mar; 63(3):107081. PubMed ID: 38176458 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017-2019. Karlowsky JA; Kazmierczak KM; Valente MLNF; Luengas EL; Baudrit M; Quintana A; Irani P; Stone GG; Sahm DF Braz J Infect Dis; 2021; 25(6):101647. PubMed ID: 34774471 [TBL] [Abstract][Full Text] [Related]
11. Results of the Italian infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-IT): activity of ceftazidime/avibactam against Enterobacterales isolated from urine. Giani T; Antonelli A; Sennati S; Di Pilato V; Chiarelli A; Cannatelli A; Gatsch C; Luzzaro F; Spanu T; Stefani S; Rossolini GM J Antimicrob Chemother; 2020 Apr; 75(4):979-983. PubMed ID: 31958125 [TBL] [Abstract][Full Text] [Related]
12. In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula. Sonnevend Á; Ghazawi A; Darwish D; Barathan G; Hashmey R; Ashraf T; Rizvi TA; Pál T Int J Infect Dis; 2020 Oct; 99():253-259. PubMed ID: 32738488 [TBL] [Abstract][Full Text] [Related]
13. Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum-β-Lactamase- and AmpC-Producing Isler B; Ezure Y; Romero JLG; Harris P; Stewart AG; Paterson DL Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33046493 [TBL] [Abstract][Full Text] [Related]
14. Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program. Lin LY; Debabov D; Chang W; Stone G; Riccobene T Antimicrob Agents Chemother; 2022 Mar; 66(3):e0198521. PubMed ID: 35225651 [No Abstract] [Full Text] [Related]
15. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014. Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635 [TBL] [Abstract][Full Text] [Related]
16. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021. Wise MG; Karlowsky JA; Mohamed N; Kamat S; Sahm DF Eur J Clin Microbiol Infect Dis; 2023 Sep; 42(9):1135-1143. PubMed ID: 37526796 [TBL] [Abstract][Full Text] [Related]
17. Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in Kawai A; McElheny CL; Iovleva A; Kline EG; Sluis-Cremer N; Shields RK; Doi Y Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32284381 [TBL] [Abstract][Full Text] [Related]